Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 641 to 650 of 2733 total matches.
Potassium Iodide for Thyroid Protection in a Nuclear Accident
The Medical Letter on Drugs and Therapeutics • Apr 04, 2011 (Issue 1361)
and cancer.1 The
risk is greatest for children, adolescents and pregnant
women. Adults more than 40 years ...
Even though it is unlikely that people living in the US
will be at risk of significant radiation exposure from the
nuclear accident in Japan, some readers have suggested
a review of the use of potassium iodide (KI) in
such circumstances. Potassium iodide taken orally
before or at the time of exposure can limit or prevent
uptake of radioactive iodine by the thyroid gland.
Invokamet and Xigduo XR - Two New Combinations for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Dec 08, 2014 (Issue 1457)
should be added to metformin, which is already
Table 1. Canagliflozin, Dapagliflozin and Combinations ...
The FDA has approved fixed-dose combinations of
metformin with either canagliflozin (Invokamet) or
dapagliflozin (Xigduo XR) for treatment of patients
with type 2 diabetes not adequately controlled
with any one of these drugs, or in those already
being treated with both metformin and either
canagliflozin or dapagliflozin.
Crisaborole (Eucrisa) for Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics • Feb 27, 2017 (Issue 1515)
,
telangiectasias, and permanent striae.1,2
The topical calcineurin inhibitors tacrolimus (Protopic,
and generics ...
The FDA has approved crisaborole 2% ointment
(Eucrisa – Pfizer) for topical treatment of mild to
moderate atopic dermatitis in patients ≥2 years old. It
is the first phosphodiesterase type-4 (PDE4) inhibitor
to be approved in the US for this indication.
Mosunetuzumab (Lunsumio) for Follicular Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • Mar 06, 2023 (Issue 1671)
follicular lymphoma.1,2
MECHANISM OF ACTION — Mosunetuzumab is a
T-cell-engaging bispecific antibody ...
Mosunetuzumab-axgb (Lunsumio – Genentech),
a bispecific CD20-directed CD3 T-cell engager,
has received accelerated approval from the FDA
for treatment of relapsed or refractory follicular
lymphoma in adults who received ≥2 lines of systemic
therapy. It is the first T-cell-engaging bispecific
antibody to be approved in the US for this indication.
Med Lett Drugs Ther. 2023 Mar 6;65(1671):e41-2 doi:10.58347/tml.2023.1671f | Show Introduction Hide Introduction
Iberdomide (Zenbexus) for Multiple Myeloma (online only)
The Medical Letter on Drugs and Therapeutics • Oct 26, 2026 (Issue 1766)
taken with strong or moderate CYP3A
inhibitors.
▶ Dosage: 1 mg taken once daily on days 1 to 21 ...
Iberdomide (Zenbexus – BMS), an oral first-in-class
cereblon-modulating protein degrader, has received
accelerated approval from the FDA for use in combination
with the CD38-directed cytolytic antibody daratumumab
(Darzalex Faspro) and dexamethasone for treatment of
multiple myeloma in adults who received at least one
prior line of therapy, including a proteasome inhibitor (e.g.,
bortezomib) and an immunomodulatory drug. The drug was
approved based on a surrogate endpoint of minimal residual
disease-negative complete response.
Med Lett Drugs Ther. 2026 Oct 26;68(1766):e175-6 doi:10.58347/tml.2026.1766e | Show Introduction Hide Introduction
Zidesamtinib (Jideytro) – Another Kinase Inhibitor for NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Oct 26, 2026 (Issue 1766)
), and taletrectinib (Ibtrozi) were approved earlier.1
Zidesamtinib (Jideytro) – Another
Kinase Inhibitor for NSCLC ...
Zidesamtinib (Jideytro – GSK), an oral kinase inhibitor, has
been approved by the FDA for treatment of locally advanced
or metastatic ROS1-positive non-small cell lung cancer
(NSCLC) in adults who received at least one prior ROS1
kinase inhibitor. It is the fifth oral kinase inhibitor to be
approved in the US for treatment of ROS1-positive NSCLC;
crizotinib (Xalkori), entrectinib (Rozlytrek), repotrectinib
(Augtyro), and taletrectinib (Ibtrozi) were approved earlier.
Med Lett Drugs Ther. 2026 Oct 26;68(1766):e177-8 doi:10.58347/tml.2026.1766f | Show Introduction Hide Introduction
Natalizumab (Tysabri) for Relapsing Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Feb 14, 2005 (Issue 1202)
, and have been
shown to be safe and effective for periods ranging
from 4 to 10 years.
1,2
MECHANISM OF ACTION ...
Natalizumab, a recombinant humanized monoclonal antibody, has received accelerated approval from the FDA for intravenous treatment of relapsing forms of multiple sclerosis (MS). The beta interferons and glatiramer acetate are widely used for treatment of MS; they generally reduce the number of relapses by about 30% compared to placebo, and have been shown to be safe and effective for periods ranging from 4 to 10 years.
Intra-Articular Injections for Osteoarthritis of the Knee
The Medical Letter on Drugs and Therapeutics • Mar 27, 2006 (Issue 1231)
for painful osteoarthritis
(OA) of the knee, have been at least somewhat discredited,
1
some patients ...
Now that glucosamine and chondroitin, 2 favorite over-the-counter remedies for painful osteoarthritis (OA) of the knee, have been at least somewhat discredited, some patients will be asking about alternatives. One of these is periodic intra-articular injection of a corticosteroid or hyaluronic acid preparation.
Phexxi - A Nonhormonal Contraceptive Gel
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020 (Issue 1605)
), but
was never marketed.1
Phexxi — A Nonhormonal
Contraceptive Gel
CHOICE OF CONTRACEPTIVES — Intrauterine ...
The FDA has approved Phexxi (Evofem), a
nonhormonal prescription-only vaginal gel containing
lactic acid, citric acid, and potassium bitartrate, for
prevention of pregnancy. The gel is intended for on-demand
contraception; it is not effective when used
after intercourse. It was previously approved for
use as a vaginal lubricant (Amphora), but was never
marketed.
Prenatal Acetaminophen Use and Autism
The Medical Letter on Drugs and Therapeutics • Dec 08, 2025 (Issue 1743)
-term neurological effects such as autism
in their children.1 The announcement cites a
“consensus ...
Acetaminophen has been considered the drug
of choice for treatment of fever and pain during
pregnancy for decades, but a recent announcement
by the US Department of Health and Human Services
(HHS) has prompted discussion about its effects on
fetal neurodevelopment and the risk of autism.
Med Lett Drugs Ther. 2025 Dec 8;67(1743):193-5 doi:10.58347/tml.2025.1743a | Show Introduction Hide Introduction
